Terms: = Lung cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802
681 results:
1.
Feng B; Wang X; Qiu D; Sun H; Deng J; Tan Y; Ji K; Xu S; Zhang S; Tang C
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732173
[TBL] [Abstract] [Full Text] [Related]
2. The effects of immortalization on the N-glycome and proteome of cdk4-transformed lung cancer cells.
Alvarez MRS; Moreno PG; Grijaldo-Alvarez SJB; Yadlapati A; Zhou Q; Narciso MP; Completo GC; Nacario RC; Rabajante JF; Heralde FM; Lebrilla CB
Glycobiology; 2024 Apr; 34(6):. PubMed ID: 38579012
[TBL] [Abstract] [Full Text] [Related]
3. Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract] [Full Text] [Related]
4. Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies.
Yokota E; Iwai M; Yukawa T; Naomoto Y; Haisa M; Monobe Y; Takigawa N; Fukazawa T; Yamatsuji T
Cancer Lett; 2024 Apr; 588():216816. PubMed ID: 38499265
[TBL] [Abstract] [Full Text] [Related]
5. Discrepancy Between Achieved and Vendor-Predicted Ablation Zones in the lung: Contributing Factors.
Xu Y; Padley SPG; Devaraj A; Desai SR; Ridge CA
Cardiovasc Intervent Radiol; 2024 May; 47(5):613-620. PubMed ID: 38361010
[TBL] [Abstract] [Full Text] [Related]
6. cdk4/6 inhibitors in lung cancer: current practice and future directions.
Lv S; Yang J; Lin J; Huang X; Zhao H; Zhao C; Yang L
Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38355149
[TBL] [Abstract] [Full Text] [Related]
7. Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.
Tan Q; Gao R; Zhang X; Yang J; Xing P; Yang S; Wang D; Wang G; Wang S; Yao J; Zhang Z; Tang L; Yu X; Han X; Shi Y
Cancer Immunol Immunother; 2024 Feb; 73(3):47. PubMed ID: 38349411
[TBL] [Abstract] [Full Text] [Related]
8. Effect of cdk4/6 Inhibitors on Tumor Immune Microenvironment.
Liu J; Cheng M; Xu J; Liang Y; Yin B; Liang J
Immunol Invest; 2024 Apr; 53(3):437-449. PubMed ID: 38314676
[TBL] [Abstract] [Full Text] [Related]
9. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
[TBL] [Abstract] [Full Text] [Related]
10. A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases.
Takeda T; Sugimoto S; Matsumoto J; Iwata N; Nakamoto A; Ozaki AF; Hamano H; Ariyoshi N; Zamami Y
Int J Clin Pharm; 2024 Apr; 46(2):536-541. PubMed ID: 38240964
[TBL] [Abstract] [Full Text] [Related]
11. Interstitial lung disease and cdk4/6 inhibitors in the treatment of breast cancer.
Schlam I; Giordano A; Tolaney SM
Expert Opin Drug Saf; 2023; 22(12):1149-1156. PubMed ID: 37994878
[TBL] [Abstract] [Full Text] [Related]
12. Icariside I reduces breast cancer proliferation, apoptosis, invasion, and metastasis probably through inhibiting IL-6/STAT3 signaling pathway.
Hou M; Li H; He T; Hui S; Dai W; Hou X; Zhao J; Zhao J; Wen J; Kan W; Xiao X; Zhan X; Bai Z
J Pharm Pharmacol; 2024 May; 76(5):499-513. PubMed ID: 37971302
[TBL] [Abstract] [Full Text] [Related]
13. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
[TBL] [Abstract] [Full Text] [Related]
14. Notopterol Suppresses IL-17-Induced Proliferation and Invasion of A549 lung Adenocarcinoma Cells via Modulation of STAT3, NF-κB, and AP-1 Activation.
Inthanon S; Dejkriengkraikul P; Yodkeeree S
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894738
[TBL] [Abstract] [Full Text] [Related]
15. Bruceine A: Suppressing metastasis via MEK/ERK pathway and invoking mitochondrial apoptosis in triple-negative breast cancer.
Li X; Liu C; Zhang X; Sun C; Ling J; Liu Y; Zuo Y; Cao Y; Zhang C; Jiang T; Wang M; Liu J; Lu J
Biomed Pharmacother; 2023 Dec; 168():115784. PubMed ID: 37879215
[TBL] [Abstract] [Full Text] [Related]
16. Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer.
Bai Y; Zhou L; Zhang C; Guo M; Xia L; Tang Z; Liu Y; Deng S
Oncogene; 2023 Dec; 42(49):3605-3618. PubMed ID: 37864031
[TBL] [Abstract] [Full Text] [Related]
17. Licochalcone A induces cell cycle arrest and apoptosis via suppressing MAPK signaling pathway and the expression of FBXO5 in lung squamous cell cancer.
Fan X; Guan G; Wang J; Jin M; Wang L; Duan X
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37859622
[TBL] [Abstract] [Full Text] [Related]
18. Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators.
Volta F; La Monica S; Leonetti A; Gnetti L; Bonelli M; Cavazzoni A; Fumarola C; Galetti M; Eltayeb K; Minari R; Petronini PG; Tiseo M; Alfieri R
Target Oncol; 2023 Nov; 18(6):953-964. PubMed ID: 37855989
[TBL] [Abstract] [Full Text] [Related]
19. Extracellular vesicles from subjects with COPD modulate cancer initiating cells phenotype through HIF-1α shuttling.
Petraroia I; Ghidotti P; Bertolini G; Pontis F; Roz L; Balsamo M; Suatoni P; Pastorino U; Ferretti AM; Sozzi G; Fortunato O
Cell Death Dis; 2023 Oct; 14(10):681. PubMed ID: 37838700
[TBL] [Abstract] [Full Text] [Related]
20. Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance.
Zheng J; Dou Y; Huang D; Wang Y; Han R; Hu C; Zhu M; Lu C; Lin C; Wu D; Liu Y; Tang H; He T; Jiang W; He Y
Jpn J Clin Oncol; 2024 Jan; 54(1):89-96. PubMed ID: 37721193
[TBL] [Abstract] [Full Text] [Related]
[Next]
